LOFIEGO MARIA FORTUNATA

Maria Fortunata
Lofiego
Ricercatore Legge 240/10 - tempo determinato

Teaching activities

Completion accademic year: 2024/2025

Course year: 3 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2022/2023

Completion accademic year: 2023/2024

Course year: 3 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2021/2022

Research

Ultime pubblicazioni:

  • Noviello, T.M.R., Di Giacomo, A.M., Caruso, F.P., Covre, A., Mortarini, R., Scala, G., et al. (2023). Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. NATURE COMMUNICATIONS, 14(1), 5914 [10.1038/s41467-023-40994-4]. - view more
  • Di Giacomo, A.M., Giacobini, G., Anichini, G., Gandolfo, C., D'Alonzo, V., Calabro, L., et al. (2022). SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines. EUROPEAN JOURNAL OF CANCER, 171, 143-149 [10.1016/j.ejca.2022.05.018]. - view more
  • Anichini, A., Molla, A., Nicolini, G., Perotti, V.E., Sgambelluri, F., Covre, A., et al. (2022). Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 41(1), 1-15 [10.1186/s13046-022-02529-5]. - view more
  • Chiarucci, C., Cannito, S., Daffina, M.G., Amato, G., Giacobini, G., Cutaia, O., et al. (2020). Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival. CANCERS, 12(2), 1-14 [10.3390/cancers12020361]. - view more
  • Maio, M., Lofiego, M.F., Fazio, C., Cannito, S., Chiarucci, C., Giacobini, G., et al. (2019). Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 68(1), 151-158 [10.1007/s00262-018-2222-0]. - view more